Skip to main content
Premium Trial:

Request an Annual Quote

BiOasis Raises C$1.7M from Warrants

NEW YORK (GenomeWeb News) – BiOasis Technologies today said that it will receive cash proceeds of C$1.7 million (US$1.4 million) from the exercise of warrants that expired on March 31.

The Vancouver, BC-based developer of therapeutics and molecular diagnostics for neurological diseases said that a result of the warrants being exercised it now has cash and cash equivalents of C$2.4 million. The additional funds will enable the firm to fund a final trial of the p97 biomarker as a diagnostic for Alzheimer's disease.

BiOasis CEO Rob Hutchinson said that the proceeds also would provide sufficient working capital "for at least the next 12 months."

The warrants comprised 6.5 million share purchase warrants, which entitled holders of each share to purchase one common share of BiOasis for C$.25 and 975,000 agent warrants, which entitled the holder of each agent warrant to purchase one common share of the firm for C$.15.

Among BiOasis' technologies is the Stable Isotope Standards and Capture by Anti-Peptide Antibodies, a proteomics platform aimed at biomarker quantification and qualification. The SISCAPA technique was developed to measure protein levels in human plasma and is based on immunoaffinity enrichment of peptide surrogates of biomarker proteins and their identification by mass spectrometry.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.